Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants.
Several classes of drugs that modify serotonin (5-HT) neurotransmission are either currently used, or are being evaluated for their potential use in the treatment of anxiety, schizophrenia, and depression. 5-HT1A agonists are considered potential anxiolytics, while some atypical antipsychotics are potent 5-HT2 antagonists (and also have modest dopamine D2 affinity). Furthermore, there is a diverse group of serotonergic drugs that may be effective antidepressants. Secretion of ACTH, corticosterone/cortisol, prolactin, renin, oxytocin and vasopressin are stimulated by activation of different 5-HT receptor subtypes, while other neurotransmitter receptors also influence the secretion of these hormones. We compared the receptor binding profiles of 5-HT anxiolytics, antipsychotics and antidepressants with their endocrine effects. These comparisons could aid in understanding both the therapeutic and side effects of these drugs.
Levy
A D
AD
Department of Pharmacology, Loyola University of Chicago, Stritch School of Medicine, Maywood, IL 60153.
Van de Kar
L D
LD
D014151:Anti-Anxiety Agents / Q000378:metabolism / Q000494:pharmacology*; D000928:Antidepressive Agents / Q000378:metabolism / Q000494:pharmacology*; D014150:Antipsychotic Agents / Q000378:metabolism / Q000494:pharmacology*; D004702:Endocrine Glands / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists / Q000378:metabolism / Q000494:pharmacology
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D012701:Serotonin